GENinCode (LON:GENI) Trading 4.1% Higher – What’s Next?

GENinCode Plc (LON:GENI)’s share price traded up 4.1% during mid-day trading on Tuesday . The company traded as high as GBX 2.30 and last traded at GBX 2.29. 517,544 shares traded hands during trading, a decline of 38% from the average session volume of 836,486 shares. The stock had previously closed at GBX 2.20.

GENinCode Stock Up 13.7%

The company has a debt-to-equity ratio of 9.28, a quick ratio of 15.89 and a current ratio of 2.60. The firm’s 50 day moving average price is GBX 2.70 and its two-hundred day moving average price is GBX 2.46. The company has a market cap of £7.17 million, a P/E ratio of -1.06 and a beta of 0.66.

GENinCode (LON:GENI) last posted its quarterly earnings results on Tuesday, September 30th. The company reported GBX (1.19) EPS for the quarter. GENinCode had a negative return on equity of 289.74% and a negative net margin of 228.70%. Equities research analysts anticipate that GENinCode Plc will post -7.1299999 EPS for the current fiscal year.

GENinCode Company Profile

GENinCode Plc is a UK based company specialising in genetic risk assessment of cardiovascular disease. Cardiovascular disease is the leading cause of death and disability worldwide.

GENinCode operates business units in the UK, in the United States through GENinCode U.S. Inc and in Europe through GENinCode S.L.U.

GENinCode predictive technology provides patients and physicians with globally leading preventative care and treatment strategies. GENinCode CE marked invitro-diagnostic molecular tests combine clinical algorithms and bioinformatics to provide advanced patient risk assessment to predict disease onset.